Maternal Immune Adaptation During Assisted Reproduction

Abstract

Assisted reproductive technologies (ART) have transformed the management of infertility, yet they present unique immunological challenges for maternal adaptation to allogeneic embryos. This review synthesizes current evidence regarding immune modulation during ART, focusing on epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, and guideline recommendations. Particular emphasis is placed on immunological mechanisms, including the balance between tolerance and immunity, and clinical implications for optimizing ART outcomes in women with immune-mediated infertility. Recent advances and future directions for research and therapy are also discussed.

Introduction

Successful human reproduction requires intricate maternal immune adaptation to tolerate the semi-allogeneic fetus. In natural conception, this process is orchestrated by a delicate interplay between the maternal immune system and the developing embryo. However, ART procedures such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) can disrupt these physiological processes, potentially increasing risks for implantation failure, miscarriage, and obstetric complications. Understanding immune adaptation in the context of ART is crucial for clinicians managing infertility and reproductive immunology cases.

Epidemiology / Disease Burden

Infertility affects approximately 8-12% of reproductive-aged couples globally, with an increasing reliance on ART due to delayed childbearing and rising prevalence of underlying reproductive disorders. ART accounts for over 2% of births in many developed countries. Immune-mediated infertility, including antiphospholipid syndrome, autoimmunity, and alloimmune disorders, is implicated in a significant proportion of recurrent implantation failure (RIF) and pregnancy loss cases in ART settings. The burden of immune-related ART complications, such as preeclampsia and preterm birth, underscores the need for better immune monitoring and intervention strategies.

Pathophysiology

Maternal immune adaptation encompasses both innate and adaptive immune responses. Key mechanisms include the modulation of uterine natural killer (uNK) cell activity, induction of regulatory T cells (Tregs), and expression of immunomodulatory molecules such as HLA-G by trophoblasts. In ART, supraphysiological hormone levels, ovarian stimulation, and embryo manipulation can lead to altered cytokine profiles, impaired recruitment of Tregs, and dysregulation of uNK cells. These changes may hinder maternal-fetal tolerance, increase inflammation at the implantation site, and contribute to poor reproductive outcomes. Recent studies highlight the importance of the Th1/Th2/Th17 balance, complement system activation, and the impact of endometrial receptivity on immune adaptation during ART.

Risk Factors

Risk factors for impaired maternal immune adaptation in ART include advanced maternal age, obesity, polycystic ovary syndrome (PCOS), endometriosis, autoimmune diseases (e.g., systemic lupus erythematosus, antiphospholipid syndrome), history of recurrent implantation failure or pregnancy loss, and genetic polymorphisms affecting immune-regulatory pathways (e.g., KIR/HLA-C mismatch). The use of donor gametes, particularly oocyte donation, increases alloimmune challenges due to greater genetic disparity between the mother and embryo. Environmental factors, infections, and coexisting metabolic or inflammatory conditions can further modulate the immune landscape during ART cycles.

Clinical Features

Impaired immune adaptation may manifest clinically as recurrent implantation failure, recurrent pregnancy loss, preeclampsia, fetal growth restriction, and preterm birth in ART pregnancies. Subtle clinical indicators include abnormal endometrial thickness, altered menstrual parameters, and unexplained infertility despite optimal ART protocols. Laboratory findings may reveal elevated antiphospholipid antibodies, antinuclear antibodies, or aberrant cytokine and immune cell profiles, although these markers are not universally predictive.

Diagnosis

Diagnosis of immune-mediated reproductive failure in ART involves a combination of clinical assessment, detailed reproductive history, and targeted immunological investigations. Recommended workup includes assessment for autoimmune and alloimmune markers, such as antiphospholipid antibody panel, antinuclear antibody testing, thrombophilia screening, and evaluation of peripheral and endometrial immune cell populations (e.g., uNK cells, Tregs). Specialized assays for cytokine profiling and HLA/KIR genotyping may inform individualized risk stratification, although their routine use remains debated. Endometrial biopsy for immune cell quantification is emerging as a valuable adjunct in select cases of unexplained ART failure.

Treatment & Management

Management strategies are tailored to the underlying immune pathology. For women with antiphospholipid syndrome or thrombophilia, low-dose aspirin and heparin are standard. Immunomodulatory therapies, such as corticosteroids, intravenous immunoglobulin (IVIg), and intralipid infusions, are used empirically in cases of suspected alloimmune dysfunction, though evidence of efficacy remains limited. Optimization of endometrial receptivity through hormonal support, lifestyle modification, and management of comorbidities is essential. Pre-ART counseling regarding immune risk factors and early obstetric surveillance can improve outcomes. Multidisciplinary collaboration between reproductive endocrinologists, immunologists, and maternal-fetal medicine specialists is recommended.

Recent Advances / Emerging Therapies

Recent advances include the identification of novel immune biomarkers predictive of ART success, such as endometrial uNK cell density and gene expression signatures. Emerging therapies under investigation encompass targeted cytokine inhibitors (e.g., anti-TNF agents), Treg-enhancing agents, and cell-based therapies aiming to restore immune tolerance. Personalized immunomodulatory protocols, incorporating molecular diagnostics and precision medicine, hold promise for improving live birth rates in women with immune-mediated ART failure. Ongoing studies are evaluating the utility of preimplantation genetic testing for aneuploidy (PGT-A) and its interplay with maternal immune adaptation.

Guideline Recommendations

Recent guidelines from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) emphasize judicious use of immunological testing and caution against routine immunotherapy in the absence of clear indications. Recommendations highlight the importance of individualized assessment, evidence-based management of autoimmune and thrombophilic states, and avoidance of unproven interventions. Ongoing research and registry data are essential to refine these guidelines and inform best practices in this evolving field.

Conclusion

Maternal immune adaptation is a critical determinant of success in assisted reproduction, with dysfunction contributing to adverse reproductive outcomes. Advances in immunological diagnostics and therapeutics are enhancing our ability to identify and manage immune-mediated infertility in the ART setting. Multidisciplinary, evidence-based approaches tailored to individual patient profiles are key to optimizing maternal and fetal outcomes. Continued translational research is warranted to further elucidate the mechanisms underlying immune adaptation and drive innovation in reproductive medicine.